f

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

Sorry, no posts matched your criteria.

Escape Rheum: Cracking the Code to Rheumatoid Arthritis Treatment

  • No products in the cart.

Escape Rheum: Cracking the Code to Rheumatoid Arthritis Treatment

Many patients with rheumatoid arthritis (RA) do not have their disease adequately controlled, and only a minority achieve consistent remission or low disease activity. This activity was designed to sharpen participants’ understanding of the evolving therapeutic landscape for RA and equip them with forward-thinking, patient-centered communication strategies. Through a combination of a mechanism of action (MOA) video, TED Talks-style presentations, a clinical case study, and a large-group discussion, participants explored MOAs of targeted therapies, the latest evidence on clinical efficacy and safety of JAK inhibitors, disease activity measures to guide treatment decisions, and use of decision aids.

  • Sheetal Desai, MD, MSEd
    Chief of Rheumatology,
    Rheumatology Fellowship Program Director,
    Director, Lupus Clinic
    Associate Clinical Professor of Medicine,
    Division of Rheumatology
    University of California, Irvine
    Irvine, California

  • Atul A. Deodhar, MD, MRCP, FACR, FACP
    Professor of Medicine,
    Medical Director of Rheumatology Clinics,
    Division of Arthritis & Rheumatic Diseases
    Oregon Health & Science University
    Portland, Oregon

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD and Christine Tebben

Presenter: Sheetal Desai, MD, MSEd

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant—AbbVie, Amgen, Boehringer Ingelheim, Bristol Meyers Squibb, Eli Lilly, Glaxo Smith & Klein, Janssen, Novartis, Pfizer, UCB
  • Advisory Board—AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Glaxo Smith & Klein, Janssen, Novartis, Pfizer, UCB
  • Contracted Research—AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Glaxo Smith & Klein, Janssen, Novartis Pfizer, UCB

Planners: Eric Ruderman, MD

  • Consultant—AbbVie, Amgen, Lilly, Novartis, Sandoz, Scipher
  • Advisory Board—AbbVie, Janssen, PfizerLinda Grinnell-Merrick, MS, NP-BC

Linda Grinnell-Merrick, MS, NP-BC

  • Advisory Board—AbbVie, Novartis, Pfizer, Horizon
  • Contracted Research—Novartis
  • Speakers’ Bureau—AbbVie, Celgene, Novartis, Janssen

Philip J. Mease, MD

  • Consultant—AbbVie, Amgen, Bristol Myers Squibb, Boehringer
    Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau—AbbVie, Amgen, Bristol Myers Squibb, Celgene,
    Genentech, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research—AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

As a result of participation in this educational activity, participants should increase their ability to:

  • Explain the MOAs of JAK inhibitors in treatment of rheumatoid arthritis (RA)

  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule agents for treatment of RA

  • Describe

    Discuss comorbidities that should be considered before starting a patient on a JAK inhibitor 

  • Apply ACR-endorsed RA disease activity measures to guide treatment decisions and evaluate treatment response in patients with RA

  • Initiate a shared decision-making conversation with patients about treatment goals and options

Resources

Unless otherwise specifically prohibited, you may temporarily download one copy of the materials for personal, noncommercial use only. You may not modify or copy the materials, use them for any commercial purpose or public display (commercial or noncommercial), remove any copyright or other proprietary notations, or transfer the materials to another person or online site.

 

Activity Information

Target Audience
The target audience for this activity was rheumatologists and NP/PA rheumatology providers. Other healthcare professionals who treat patients with RA may have benefited from participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ACCME: Forefront Collaborative designated this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

This continuing medical education activity included reference(s) to unlabeled or unapproved uses of drugs or devices.

Provider
This activity is provided by Forefront Collaborative.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.